Department of Pharmaceutics and Pharmaceutical Technology, College of Pharmacy, University of Sharjah, Sharjah 27272, United Arab Emirates; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo 71526, Egypt.
Department of Pharmaceutics and Pharmaceutical Technology, College of Pharmacy, University of Sharjah, Sharjah 27272, United Arab Emirates.
J Adv Res. 2022 Jul;39:237-255. doi: 10.1016/j.jare.2021.11.008. Epub 2021 Nov 20.
Colorectal cancer (CRC) is the third most prevalent type of cancer for incidence and second for mortality worldwide. Late diagnosis and inconvenient and expensive current diagnostic tools largely contribute to the progress of the disease. The use of chemotherapy in the management of CRC significantly reduces tumor growth, metastasis, and morbidity rates. However, poor solubility, low cellular uptake, nonspecific distribution, multiple drug resistance and unwanted adverse effects are still among the major drawbacks of chemotherapy that limit its clinical significance in the treatment of CRC. Owing to their remarkable advantages over conventional therapies, the use of nanotechnology-based delivery systems especially polymeric nanocarriers (PNCs) has revolutionized many fields including disease diagnosis and drug delivery.
In this review, we shed the light on the current status of using PNCs in the diagnosis and treatment of CRC with a special focus on targeting strategies, surface modifications and safety concerns for different types of PNCs in colonic cancer delivery.
The review explores the current progress on the use of PNCs in the diagnosis and treatment of CRC with a special focus on the role of PNCs in improvement of cellular uptake, drug targeting and co-delivery of chemotherapeutic agents. Possible toxicity and biocompatibility issues related to the use of PNCs and imitations and future recommendation for the use of those smart carriers in the diagnosis and treatment of CRC are also discussed.
结直肠癌(CRC)是全球发病率第三高、死亡率第二高的癌症。诊断较晚以及目前诊断工具不便且昂贵,在很大程度上导致了疾病的进展。化疗在 CRC 的治疗中显著降低了肿瘤生长、转移和发病率。然而,溶解度差、细胞摄取率低、非特异性分布、多药耐药性和不良的副作用仍然是化疗的主要缺点,限制了其在 CRC 治疗中的临床意义。由于纳米技术为基础的递送系统,特别是聚合物纳米载体(PNC)在疾病诊断和药物递送等领域的卓越优势,对许多领域进行了彻底的改革。
在本综述中,我们重点介绍了 PNC 在 CRC 的诊断和治疗中的应用现状,特别关注不同类型 PNC 在结直肠癌递送上的靶向策略、表面修饰和安全性问题。
本综述探讨了 PNC 在 CRC 的诊断和治疗中的应用现状,特别关注 PNC 在提高细胞摄取、药物靶向和化疗药物共递送上的作用。还讨论了与使用 PNC 相关的可能毒性和生物相容性问题,以及对这些智能载体在 CRC 的诊断和治疗中的使用的限制和未来建议。